Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

625.O1.8 DLBCL and Other NHL: Novel Therapeutic Targets and Approaches

Monday, December 8, 2008: 3:30 PM-5:30 PM
3006-3008 - West (Moscone Center)
Moderators:
Izidore Lossos and Miles Prince
3:30 PM
Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc

Kristopher A Sarosiek1*, Hovav Nechushtan, MD, PhD2*, Eli Avisar, MD3* and Izidore S Lossos, MD4

1Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL
2Department of Medicine, Division of Hematology, University of Miami, Miami, FL, United States
3Department of Surgery, University of Miami, Miami, FL
4Department of Medicine, Division of Hematology, University of Miami, Miami, FL

3:45 PM
Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma

Eloisi Caldas Lopes1*, Leandro Cerchietti2*, Shao Ning Yang2*, Ari Melnick2 and Gabriela Chiosis1*

1Molecular Pharmacology & Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY
2Hematology and Oncology Division, Weill Cornell Medical College, New York, NY

4:00 PM
Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma

Mamta Gupta, PhD, Stephen M. Ansell*, Anne J. Novak* and Thomas E. Witzig*

Division of Hematology, Mayo Clinic, Rochester, MN

4:15 PM
Onco-Mir-155 Targets SHIP to Regulate TNF-Dependent B-Cell Lymphoma Growth

Irene Munk Pedersen1, Dennis C Otero1*, Elaine Kao1*, Ana Sedy2*, Christoffer Hother3*, Elisabeth Ralfkiaer4*, Robert C Rickert2*, Kirsten Gronbaek3* and Michael David1*

1Univ. of Calif.-San Diego, La Jolla, CA
2Burnham Institute for Mediacal Reseach, La Jolla, CA
3Hematology, Copenhagen University Hospital, Copenhagen, Denmark
4Pathology, Copenhagen University Hospital, Copenhagen, Denmark

4:30 PM
The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphoma (B-NHL) Cells

Francisco J. Hernandez-Ilizaliturri, MD1, Sapna Khubchandani, MD2*, Scott H. Olejniczak, PhD2*, Paul Hosking, MD2*, Elizabeth Gruber, MS2* and Myron Czuczman, MD1

1Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, NY
2Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY

4:45 PM
MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

Michael Milhollen, MSc*, Usha Narayanan*, Allison J Berger, PhD*, Michael Thomas*, Tary Traore*, Jie Yu*, Julie Zhang*, Erik Koenig*, James J. Garnsey*, Steven P. Langston*, Teresa A Soucy, PhD* and Peter G Smith, PhD*

Oncology, Millennium Pharmaceuticals, the Takeda Oncology Company, Cambridge, MA

5:00 PM
Epigenetic Silencing of BIM Mediates Chemotherapy Resistance of Patients with Burkitt Lymphoma That Can Be Overcome by Therapeutic Reactivation of BIM in Mouse and Human Lymphoma ModelsClinically Relevant Abstract

Jose A. Richter, MSc1*, Antonio Rullan1*, Elena Beltran, MSc1*, Xabier Agirre, PhD1*, M.ª José Calasanz, PhD2*, Jose Roman-Gomez, MD3*, Carlos Panizo, MD4*, Jesus M Hernandez, MD, PhD5*, Felipe Prosper, MD4, Vicente Fresquet, PhD1* and Jose A. Martinez-Climent, MD, PhD1

1Oncology Division, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain
2Department of Genetics, University of Navarra, Pamplona, Spain
3Department of Hematology, Reina Sofia Hospital, Cordoba, Spain
4Hematology & Cell Therapy Prog., Clinica Universitaria de Navarra, Pamplona, Spain
5Department of Hematology, Hospital Univeristario, Salamanca, Spain

5:15 PM
Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma

Elena Beltran, MSc1*, Vicente Fresquet, PhD1*, Jose A Richter, MSc1*, Miguel A. Piris, MD2*, Reiner Siebert, MD3* and Jose A. Martinez-Climent, MD, PhD1

1Oncology Division, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
2Molecular Pathology Program, CNIO, Madrid, Spain
3Department of Human Genetics, Christian-Albrechts-University, Kiel, Germany

*signifies non-member of ASH